1992

Company establishment

1995

5 μg/0.5ml/standard hepatitis B vaccine meets Merck's quality standards

Obtaining the Ministry of Health trial production approval number

1998

Obtained the official approval number from the State Food and Drug Administration

2000

Hepatitis B vaccine passed GMP certification for the first time

2002

Successfully Developed 10 μg/1.0ml/Standard Hepatitis B Vaccine for Adults

2004

Successfully developed the first three-year hepatitis B vaccine in China

2005

Add 10μg/0.5ml/piece of standard hepatitis B vaccine for adults, replacing 10μg/1.0ml/piece size

Hepatitis B vaccine passed GMP certification for the second time

2008

After the strategic reorganization, Beijing Minhai Biotechnology Co., Ltd. became a wholly-owned subsidiary of Kangtai Biotechnology

2010

First domestically developed 60μg/1.0ml/counter hepatitis B vaccine for adult non-response population

Hepatitis B vaccine passed GMP certification for the third time

2011

Successfully developed adult 20μg/1.0ml/support hepatitis B vaccine

Successfully developed 10g/0.5ml/standard hepatitis B vaccine for children

2012

Haemophilus influenzae type b conjugate vaccine passed GMP certification

Acellular Baidubai Haemophilus influenzae combined vaccine passed GMP certification

2013

Measles Rubella Combined with Live Attenuated Vaccine Passes GMP Certification

2014

Hepatitis B vaccine passed the 2010 version of GMP certification

Haemophilus influenzae type b conjugate vaccine (pre-filled) passed GMP certification

2017

The company is listed on the GEM of Shenzhen Stock Exchange, stock code 300601

In October,Kangtai Guangming base was officially put into use

23-Valent Pneumonia Vaccine received lot release and was officially launched into market

Start construction of COVID-19 inactivated vaccine production workshop in Nanshan district,Shenzhen;

Signs deal with AstraZeneca on development and industrialization of a COVID-19 vaccine based on adenovirus vector